dc.contributor.author | Çetin, Bülent | |
dc.contributor.author | Özet, Ahmet | |
dc.date.accessioned | 2020-12-19T19:50:40Z | |
dc.date.available | 2020-12-19T19:50:40Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Cetin, B., & Ozet, A. (2016). HER2/neu as target in gastric adenocarcinoma. Translational gastroenterology and hepatology, 1, 59. https://doi.org/10.21037/tgh.2016.06.08 | en_US |
dc.identifier.issn | 2415-1289 | |
dc.identifier.uri | https://doi.org/10.21037/tgh.2016.06.08 | |
dc.identifier.uri | https://hdl.handle.net/11436/2456 | |
dc.description | WOS: 000387679500005 | en_US |
dc.description | PubMed: 28138626 | en_US |
dc.description.abstract | Gastric adenocarcinoma (GAC), a heterogeneous disease characterized by epidemiologic and histopathologic differences across countries, is a leading cause of cancer-related death. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Ame Publ Co | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Endoscopic biopsies | en_US |
dc.subject | Resection specimens | en_US |
dc.subject | Gene amplification | en_US |
dc.subject | Matched biopsy | en_US |
dc.subject | Cancer | en_US |
dc.subject | Esophageal | en_US |
dc.title | HER2/neu as target in gastric adenocarcinoma | en_US |
dc.type | editorial | en_US |
dc.contributor.department | RTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
dc.contributor.institutionauthor | Çetin, Bülent | |
dc.identifier.doi | 10.21037/tgh.2016.06.08 | |
dc.identifier.volume | 1 | en_US |
dc.ri.edit | oa | en_US |
dc.relation.journal | Translational Gastroenterology and Hepatology | en_US |
dc.relation.publicationcategory | Diğer | en_US |